CASPIAN Proves Too Choppy For AZ Imfinzi/Tremelimumab Combo

But Imfinzi Benefit Reinforced For Small Cell Lung Cancer

Another day and another fail for AstraZeneca's combination of Imfinzi and tremelimumab, this time for extensive-stage small-cell lung cancer.

Baku_City
CASPIAN not so serene for tremelimumab • Source: Shutterstock

AstraZeneca PLC's faith in the benefits of combining the firm's checkpoint inhibitor Imfinzi with its experimental anti-CTLA-4 monoclonal antibody tremelimumab has been shaken once again as it failed to improve overall survival in patients with late-stage small cell lung cancer (SCLC), although Imfinzi monotherapy did improve OS.

More from Clinical Trials

RemeGen Fast-Tracks Potential World-First BLys/APRIL Agent For gMG In Global Phase III Trial

 

RemeGen is planning to complete enrolment in the global Phase III RemeMG study with telitacicept in generalized myasthenia gravis by the end of 2025 or early 2026. The Chinese firm has already sidelined two other global Phase III trials with the molecule to prioritize the indication.

Equillium Seeks Accelerated Approval For GVHD Drug Despite Primary Endpoint Miss

 

The biotech is banking on itolizumab’s longer-term efficacy as well as unmet need in frontline acute graft-versus-host disease as it prepares to meet with the FDA.

Almirall CEO Sounds Alarm Over Europe’s Reduced Competitiveness

 
• By 

The head of the Spanish medical dermatology specialist told Scrip that maintaining the status quo will only result in the continent’s life sciences sector slipping further behind the US and China.

Wave Aspires To Accelerated Approval In DMD With 48-Week Data

 
• By 

With its exon 53-skipping candidate already showing promise in 24-week data, Wave now has 48-week data showing improvements in muscle health and functional outcomes.

More from R&D

Stock Buyback Is Vote Of Confidence From Genmab Board

 
• By 

The Danish firm is spending nearly $580m to repurchase up to 2.2 million shares

Cassava At Crossroads As Simufilam Finally Exits, Stage Left

 

The Texas-based firm is giving up on the investigational Alzheimer’s therapy after a second Phase III failure left it with nowhere to go in the disease.

Sanofi Nabs Priority Review For MS Drug Tolebrutinib

 
• By 

A decision from the FDA is due by 28 September.